188 related articles for article (PubMed ID: 30125643)
1. CK2 inhibition protects white matter from ischemic injury.
Baltan S; Bastian C; Quinn J; Aquila D; McCray A; Brunet S
Neurosci Lett; 2018 Nov; 687():37-42. PubMed ID: 30125643
[TBL] [Abstract][Full Text] [Related]
2. CK2 inhibition confers functional protection to young and aging axons against ischemia by differentially regulating the CDK5 and AKT signaling pathways.
Bastian C; Quinn J; Tripathi A; Aquila D; McCray A; Dutta R; Baltan S; Brunet S
Neurobiol Dis; 2019 Jun; 126():47-61. PubMed ID: 29944965
[TBL] [Abstract][Full Text] [Related]
3. Casein Kinase 2 Signaling in White Matter Stroke.
Nguyen H; Zhu W; Baltan S
Front Mol Biosci; 2022; 9():908521. PubMed ID: 35911974
[TBL] [Abstract][Full Text] [Related]
4. NOS3 Inhibition Confers Post-Ischemic Protection to Young and Aging White Matter Integrity by Conserving Mitochondrial Dynamics and Miro-2 Levels.
Bastian C; Zaleski J; Stahon K; Parr B; McCray A; Day J; Brunet S; Baltan S
J Neurosci; 2018 Jul; 38(28):6247-6266. PubMed ID: 29891729
[TBL] [Abstract][Full Text] [Related]
5. CK2 is a novel negative regulator of NADPH oxidase and a neuroprotectant in mice after cerebral ischemia.
Kim GS; Jung JE; Niizuma K; Chan PH
J Neurosci; 2009 Nov; 29(47):14779-89. PubMed ID: 19940173
[TBL] [Abstract][Full Text] [Related]
6. Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy - potential clinical relevance.
D'Amore C; Borgo C; Sarno S; Salvi M
Cell Oncol (Dordr); 2020 Dec; 43(6):1003-1016. PubMed ID: 33052585
[TBL] [Abstract][Full Text] [Related]
7. Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945.
Rosales M; Rodríguez-Ulloa A; Besada V; Ramón AC; Pérez GV; Ramos Y; Guirola O; González LJ; Zettl K; Wiśniewski JR; Perera Y; Perea SE
Cells; 2021 Feb; 10(2):. PubMed ID: 33562780
[TBL] [Abstract][Full Text] [Related]
8. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.
Pierre F; Chua PC; O'Brien SE; Siddiqui-Jain A; Bourbon P; Haddach M; Michaux J; Nagasawa J; Schwaebe MK; Stefan E; Vialettes A; Whitten JP; Chen TK; Darjania L; Stansfield R; Bliesath J; Drygin D; Ho C; Omori M; Proffitt C; Streiner N; Rice WG; Ryckman DM; Anderes K
Mol Cell Biochem; 2011 Oct; 356(1-2):37-43. PubMed ID: 21755459
[TBL] [Abstract][Full Text] [Related]
9. 4,5,7-Trisubstituted indeno[1,2-b]indole inhibits CK2 activity in tumor cells equivalent to CX-4945 and shows strong anti-migratory effects.
Birus R; El-Awaad E; Ballentin L; Alchab F; Aichele D; Ettouati L; Götz C; Le Borgne M; Jose J
FEBS Open Bio; 2022 Feb; 12(2):394-411. PubMed ID: 34873879
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity.
Quotti Tubi L; Gurrieri C; Brancalion A; Bonaldi L; Bertorelle R; Manni S; Pavan L; Lessi F; Zambello R; Trentin L; Adami F; Ruzzene M; Pinna LA; Semenzato G; Piazza F
J Hematol Oncol; 2013 Oct; 6():78. PubMed ID: 24283803
[TBL] [Abstract][Full Text] [Related]
11. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
Siddiqui-Jain A; Drygin D; Streiner N; Chua P; Pierre F; O'Brien SE; Bliesath J; Omori M; Huser N; Ho C; Proffitt C; Schwaebe MK; Ryckman DM; Rice WG; Anderes K
Cancer Res; 2010 Dec; 70(24):10288-98. PubMed ID: 21159648
[TBL] [Abstract][Full Text] [Related]
12. Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma.
Zheng Y; McFarland BC; Drygin D; Yu H; Bellis SL; Kim H; Bredel M; Benveniste EN
Clin Cancer Res; 2013 Dec; 19(23):6484-94. PubMed ID: 24036851
[TBL] [Abstract][Full Text] [Related]
13. Comparing the efficacy and selectivity of Ck2 inhibitors. A phosphoproteomics approach.
Borgo C; Cesaro L; Hirota T; Kuwata K; D'Amore C; Ruppert T; Blatnik R; Salvi M; Pinna LA
Eur J Med Chem; 2021 Mar; 214():113217. PubMed ID: 33548633
[TBL] [Abstract][Full Text] [Related]
14. Effects of CK2β subunit down-regulation on Akt signalling in HK-2 renal cells.
Alcaraz E; Vilardell J; Borgo C; Sarró E; Plana M; Marin O; Pinna LA; Bayascas JR; Meseguer A; Salvi M; Itarte E; Ruzzene M
PLoS One; 2020; 15(1):e0227340. PubMed ID: 31910234
[TBL] [Abstract][Full Text] [Related]
15. Protein kinase CK2 impact on intracellular calcium homeostasis in prostate cancer.
Afzal M; Kren BT; Naveed AK; Trembley JH; Ahmed K
Mol Cell Biochem; 2020 Jul; 470(1-2):131-143. PubMed ID: 32436081
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic CK2 inhibition attenuates diverse prosurvival signaling cascades and decreases cell viability in human breast cancer cells.
Gray GK; McFarland BC; Rowse AL; Gibson SA; Benveniste EN
Oncotarget; 2014 Aug; 5(15):6484-96. PubMed ID: 25153725
[TBL] [Abstract][Full Text] [Related]
17. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.
Mandato E; Nunes SC; Zaffino F; Casellato A; Macaccaro P; Tubi LQ; Visentin A; Trentin L; Semenzato G; Piazza F
Curr Cancer Drug Targets; 2018; 18(6):608-616. PubMed ID: 28460620
[TBL] [Abstract][Full Text] [Related]
18. Protein Kinase CK2 Controls the Fate between Th17 Cell and Regulatory T Cell Differentiation.
Gibson SA; Yang W; Yan Z; Liu Y; Rowse AL; Weinmann AS; Qin H; Benveniste EN
J Immunol; 2017 Jun; 198(11):4244-4254. PubMed ID: 28468969
[TBL] [Abstract][Full Text] [Related]
19. Effects of
Zhang J; Chen S; Shi W; Li M; Zhan Y; Yang L; Zou H; Lei J; Chai X; Gao K; Liu J; Wang W; Wang Y; Zhao H
Cell Transplant; 2019 Jun; 28(6):671-683. PubMed ID: 30284459
[No Abstract] [Full Text] [Related]
20. Discovery of 5-(3-Chlorophenylamino)benzo[
Wang Y; Lv Z; Chen F; Wang X; Gou S
J Med Chem; 2021 Apr; 64(8):5082-5098. PubMed ID: 33834781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
